Clovis Oncology (CLVSQ) 10-Q2014 Q3 Quarterly report

Filed: 7 Nov 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AbbVie, Additionally, appointing, assert, Astra, automated, avoiding, bear, beneficial, BGJ, bifurcation, blank, block, borrow, broad, calendar, call, cancellation, catastrophic, charter, check, committee, comply, consecutive, consent, constitute, conversion, court, cover, coverage, creating, criteria, cured, Debio, Debiopharm, decision, default, Defense, depressed, designee, deterring, difficult, diminishing, discourage, discouraging, disproportionate, diversion, doubt, dovitinib, dramatic, Eli, employing, equitable, equivalent, event, exceed, expenditure, expiration, expire, expressly, extent, extreme, fall, feature, FGFR, flow, forfeited, forfeiture, forward, frustrate, fundamental, GilotrifTM, GlaxoSmithKline, grace, guidance, HEC, holder, Human, impossible, indenture, infringe, infringement, infringing, injunctive, intellectual, intensify, interference, introduction, invalid, Johnson, joint, junior, key, larotinib, law, lesser, life, Lilly, lose, lower, LY, manner, Mellon, merging, merit, monetary, NASDAQ, notification, olaparib, opportunity, ownership, PDGF, pending, percentage, perception, political, preceding, premium, prevent, preventing, prohibiting, proposing, proprietary, provision, PTO, published, quotation, rank, recapitalizing, redeem, redeemed, redemption, redesign, reexamination, refinance, relapsed, relief, removal, remove, repay, repayment, replace, reserved, restructuring, scheduled, scientific, service, Servicing, settlement, short, significantly, Similarly, sinking, staggered, standard, stockholder, subordinated, system, trade, trading, treasury, treble, Trust, trustee, unamortized, undergo, unenforceable, unsecured, VEGF, veliparib, volatile, volatility, waived, wide, withdrawal, written, York, Zeneca

Removed: amendment, America, attributable, behalf, calculation, decrease, employment, IND, kit, percent, registration, relation, separate, twelve, wholly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CLVSQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended September 30, 2014, as filed with the Securities and Exchange Commission (the “Report”), Erle T. Mast, as Chief Financial Officer of the Company, does hereby certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to his knowledge:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2014

/s/ ERLE T. MAST

Erle T. Mast

Executive Vice President and Chief Financial Officer